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FTD frontotemporal dementia
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In addition, standard abbreviations of amino acids and approved symbols of
human genes and proteins are used.
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ABSTRACT
The aim of this study was to find and describe the genetic background of a new
form  of  spinal  muscular  atrophy  (SMA).  Late-onset  spinal  motor
neuronopathy (LOSMoN), later named spinal muscular atrophy, Jokela type
(SMAJ),  is  a  relatively  benign  autosomal  dominant  form  of  a  lower  motor
neuron disorder. Disease onset is after the age of 30-40 years, and SMAJ is
characterized by initial painful cramps and fasciculations affecting the
proximal and distal muscles of the upper and lower limbs. The disease is slowly
progressive, resulting in weakness and mild to moderate muscle atrophy later
in life.
SMAJ was originally identified in two families in Eastern Finland. The
genome-wide scan study performed for these families showed that the disease
is linked to chromosome 22q11.2-q13.2. The disease-associated haplotype was
identical in both families, suggesting a founder effect. The founder hypothesis
was also confirmed later, as several other unrelated patients carrying the same
haplotype were identified.
The disease-causing mutation, c.197G>T p.G66V in CHCHD10, was detected
by whole-genome sequencing. The mutation was present in all then identified
55 SMAJ patients belonging to 17 families. At the same time, other dominant
mutations in CHCHD10 were described to cause a wide range of neurological
disorders. CHCHD10 was the first SMA-causing gene identified that encodes
for a mitochondrial protein.
The  prevalence  and  clinical  outcome  of CHCHD10 mutations in Finnish
neuromuscular disease patients were clarified in a screening study. The only
detected mutation was c.197G>T p.G66V, and all patients carrying this
mutation  had  a  phenotype  restricted  to  SMAJ.  The  prevalence  of  c.197G>T
p.G66V was estimated to be around 4/100 000 in Finland, i.e. approximately
200 symptomatic SMAJ patients.
The  results  of  this  study  confirm  that  SMAJ  is  a  genetically  distinct  entity
caused by a dominant mutation c.197G>T p.G66V in CHCHD10. This finding
enables genetic testing of SMAJ, providing patients with an accurate diagnosis
and  prognosis.  According  to  our  genotyping  results,  c.197G>T  p.G66V  is  a
founder mutation in Finland, all SMAJ patients having common ancestry.
SMAJ was shown to be relatively common in Finland.  It  is  clearly the most
common CHCHD10-related  disease  reported,  and  in  Finland  it  may  be  the
most  common form of  SMA.  Because  SMAJ seems to  be  absent  from other
populations, it can be considered a part of the Finnish disease heritage.
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TIIVISTELMÄ
Tämän tutkimuksen tavoitteena oli kuvata LOSMoN-taudin eli myöhään
alkavan spinaalisen motoneuronitaudin geneettinen tausta. LOSMoN, joka
sittemmin nimettiin Jokela-tyypin spinaaliseksi lihasatrofiaksi (SMAJ), on
suhteellisen lievä, autosomissa vallitsevasti periytyvä alemman motoneuronin
sairaus. Tauti alkaa 30-40 vuoden iässä, ja sen alkuoireita ovat kivuliaat
lihaskrampit ja lihasnykinät, joita esiintyy proksimaalisesti ja distaalisesti
sekä ala- että yläraajoissa. Tauti on hitaasti etenevä, ja se johtaa lihasten
heikkouteen sekä lievään tai keskivaikeaan lihasten surkastumiseen
myöhäisellä iällä.
SMAJ tunnistettiin alun perin kahdessa itäsuomalaisessa perheessä. Koko
genomin kartoituksessa näiden perheiden taudin havaittiin kytkeytyvän
kromosomialueeseen 22q11.2-q13.2. Tautiin kytkeytyvä haplotyyppi oli
molemmissa perheissä samanlainen, mikä viittaa siihen, että perheiden
taudilla on yhteinen alkuperä. Tämä perustajavaikutus saatiin vahvistettua,
kun tutkimuksessa löydettiin muita, alkuperäisiin perheisiin kuulumattomia
potilaita, joilla oli sama tautiin kytkeytyvä haplotyyppi.
Taudin aiheuttava mutaatio, CHCHD10-geenin muutos c.197G>T p.G66V,
löydettiin koko genomin sekvensoinnilla. Kyseinen mutaatio havaittiin
kaikilta siihen mennessä tunnistetuilta 55 SMAJ-potilaalta, jotka kuuluivat 17
eri perheeseen. Samaan aikaan CHCHD10-geenin muiden vallitsevasti
periytyvien mutaatioiden kuvattiin aiheuttavan erilaisia neurologisia
sairauksia. CHCHD10 oli ensimmäinen mitokondriaalista proteiinia koodaava
geeni, jonka on kuvattu aiheuttavan spinaalista lihasatrofiaa.
CHCHD10-geenin mutaatioiden yleisyyttä ja niiden aiheuttamia tauteja
selvitettiin suomalaisille neuromuskulaaritautipotilaille toteutetussa
seulontatutkimuksessa. Ainoa tutkimuksessa havaittu mutaatio oli c.197G>T
p.G66V, ja kaikkien sitä kantavien potilaiden taudinkuva vastasi SMAJ:a.
Mutaation c.197G>T p.G66V yleisyydeksi Suomessa arvioitiin noin 4/100
000, mikä tarkoittaa noin 200 oireista SMAJ-potilasta.
Tämä tutkimus osoitti, että SMAJ on geneettisesti erillinen tauti, joka johtuu
vallitsevasti periytyvästä CHCHD10-geenin c.197G>T p.G66V –mutaatiosta.
Tutkimuksen tulosten myötä SMAJ:lle on voitu kehittää geenitesti, jonka
avulla potilaat voivat saada taudilleen oikean diagnoosin ja ennusteen.
Genotyypitystulokset osoittivat, että c.197G>T p.G66V on perustajamutaatio
suomalaisväestössä. Tämän tutkimuksen perusteella SMAJ on Suomessa
suhteellisen yleinen tauti. SMAJ on selvästi yleisin CHCHD10-geeniin
11
liitetyistä taudeista, ja Suomessa se on mahdollisesti yleisin SMA:n muoto.




Inherited  disorders  are  diseases  that  have  a  genetic  background.  Although
individual genetic disorders are rare, together they are present in at least 2 %
of all neonates and affect 5 % of the population by the age of 25 (Turnpenny et
al., 2005). In monogenic diseases, identification of the causative gene is very
important because it enables immediate clinical diagnostics by genetic testing,
genetic counseling, and the development of possible therapeutic interventions.
Recent advances in next-generation sequencing technologies have unveiled a
growing  number  of  new  genetic  disorders.  Identification  of  the  pathogenic
mutation  may  still  be  complicated  if  no  knowledge  of  the  gene  function  is
available  and/or  there  are  not  enough  patients  for  segregation  studies.
Furthermore,  it  may  be  challenging  to  determine  the  significance  of  the
variants identified, leaving many findings classified as variants of unknown
significance (Richards et al., 2015).
Motor neuron diseases (MNDs) are a heterogeneous group of diseases that
result from progressive death of motor neurons. MNDs are generally classified
according to whether the degeneration affects upper motor neurons, lower
motor  neurons,  or  both.  The  most  common  MND  is  amyotrophic  lateral
sclerosis  (ALS),  which  progressively  affects  both  upper  and  lower  motor
neurons,  leading  to  death  usually  within  3-5  years  of  onset  of  symptoms.
MNDs affecting only upper motor neurons are classified mainly as hereditary
spastic paraplegias (HSPs), whereas MNDs involving specifically lower motor
neurons  are  spinal  muscular  atrophies  (SMAs).  However,  the  clinical  and
genetic  overlap  of  these  diseases  is  considerable  (James  and  Talbot,  2006;
Rossor et al., 2012).
SMAs form a category of inherited disorders characterized by degeneration of
motor neurons in the spinal cord, leading to symmetric muscle weakness and
atrophy.  Despite  advances  in  SMA  research,  the  molecular  basis  and
phenotypic spectrum of SMA are not fully understood. An increasing number
of ubiquitously expressed genes have been identified as the genetic cause of
SMA.  Nevertheless,  causative  mutations  are  identified  in  up  to  35.6%  of
patients (Bansagi et al., 2017), leaving most patients without definitive
diagnosis.
Late-onset  spinal  motor  neuronopathy  (LOSMoN)  is  a  new  form  of  slowly
progressive  autosomal  dominant  SMA  that  has  been  described  in  Finnish
patients. Clinical characteristics of LOSMoN do not directly match any of the
previously reported autosomal dominant SMA disorders (Jokela et al., 2011).
The studies presented in this thesis aim to describe the genetic background of
this novel clinical entity.
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2 REVIEW OF THE LITERATURE
2.1 Introduction to molecular genetics
The human genome consists of chromosomes, i.e. large DNA molecules that
contain the genetic information. The DNA molecule is composed of two chains
of  nucleotides  arranged  in  a  double  helix  (Watson  and  Crick,  1953).  The
nucleotides, namely adenine, thymine, cytosine, and guanine, hold the DNA
chains together by pairing with each other and are hence referred to as base
pairs  (bp).  The  human  genome  is  approximately  3  000  000  000  bp  in  size
(International Human Genome Sequencing Consortium, 2004). However,
only  1.5% of  the  human genome is  estimated  to  be  protein  coding,  the  rest
being associated with non-coding RNA molecules, repetitive elements,
introns,  pseudogenes,  regulatory  regions,  and  sequences  for  which  the
function is still unknown.
2.1.1 Genes
Genes  are  genomic  units  that  code  for  proteins  or  RNA  molecules.  The
structure  of  a  gene  consists  of  a  promoter  region,  which  regulates  the
expression of the gene, coding parts, called exons, and non-coding parts, called
untranslated  regions  (UTRs)  and  introns  (Figure  1).  In  addition  to  the
promoter, the gene may have other regulatory elements, such as enhancers
and  silencers,  which  are  often  located  far  from  the  actual  gene.  Regulatory
elements control the expression, i.e. transcription of the gene. In transcription,
the genetic information is transmitted from DNA to messenger RNA (mRNA).
The transcribed pre-mRNA is modified by removing the introns (splicing) and
adding  a  5’  cap  and  a  poly-A  tail.  In  alternative  splicing,  also  some  exonic
sequences may be removed. A single gene can produce several different mRNA
and protein isoforms that may have distinct functions. The mature mRNA is
transported from the nucleus to the cytoplasm and translated to amino acids
that form the final protein. Only coding parts of exons are translated, whereas
the 5’ cap, UTRs and poly-A tail regulate the translation. A simple scheme of
gene function is presented in Figure 1 (Strachan and Read, 2011).
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Figure 1. Structure and function of a protein-coding gene. In transcription, both coding and
non-coding parts of the gene are transcribed. The resulting pre-mRNA is modified so that
introns are spliced away and the 5’ cap and poly-A tail are added. The mature mRNA is
transported to the cytoplasm and translated to form the final protein product.
2.1.2 Microsatellites
Microsatellites are tandemly repeated DNA sequences. They consist of blocks
of  sequences  with  units  less  than  ten  nucleotides  long.  Most  of  the
microsatellites are located in non-coding parts of the genome, but in humans
approximately 17% of genes contain repeats within their open reading frames
(Gemayel et al., 2010). Microsatellites are extremely unstable because they are
prone to errors in both recombination and replication, resulting in an increase
or decrease of the repeating unit. Therefore, microsatellites are highly
polymorphic  and  they  are  often  used  as  markers  in  linkage  analysis.  Some
repeat expansion mutations of microsatellites are also known to cause human
disease,  such  as  the  neuromuscular  disorders  spinal  and  bulbar  muscular
atrophy  (SBMA)  (La  Spada  et  al.,  1991),  myotonic  dystrophy  type  1  and  2
(Brook et al., 1992; Liquori et al., 2001) and frontotemporal dementia and/or
amyotrophic lateral sclerosis 1 (FTDALS1) (DeJesus-Hernandez et al., 2011;
Renton et al., 2011).
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2.1.3 Mutations
Mutation is  a  change in the genetic  material.  Some mutations are harmless
variants, i.e. polymorphisms, whereas others are pathogenic. The vast
majority of mutations occur spontaneously through errors in DNA replication
or repair, but they can also be caused by a mutagen, such as ionizing radiation,
DNA reactive chemicals  or  viruses.  Only mutations affecting germ-line cells
can be transmitted to future generations. There are different types of
mutations  (Table  1),  of  which  substitution  being  the  most  common
(Turnpenny et al., 2005; Strachan and Read, 2011).
Table 1. Different types of mutations.
Mutation type Definition Subtype Location Consequence
Substitution










Change of an amino












Change in splice site
recognition
Deletion
Loss of one or more





Loss of reading frame





Deletion of one or
more amino acids
Insertion
Insertion of one or more





Loss of reading frame









Large deletion / insertion -
One or more
exons / genes











of a repeating unit
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2.1.4 Modes of Mendelian inheritance
If  a  trait  or  disorder  is  caused  by  a  mutation(s)  in  a  single  gene,  it  exhibits
monogenic or Mendelian inheritance. According to the Online Mendelian
Inheritance in Man database (OMIM, 16.4.2018), there are 5 219 monogenic
human disorders and traits for which the molecular basis is known. If a gene
that  determines  a  trait  is  on  an  autosome,  it  is  said  to  show  autosomal
inheritance. A trait is called dominant if it manifests in heterozygous state, i.e.
only  one  mutated  allele  causes  the  phenotype.  A  parent  with  an  autosomal
dominant trait has a 50% risk of transmitting the trait to his or her child. A
recessive trait requires both alleles to be mutated, this means either
homozygosity or compound heterozygosity. Thus, both parents need to carry
at least one mutation in order to have an affected child, the risks being 25% for
an affected child, 50% for an unaffected carrier and 25% for an unaffected non-
carrier.
Sex-linked  inheritance  involves  a  gene  mutation  on  either  the  X-  or  Y-
chromosome. Y-chromosomal inheritance is very rare, but already 324 X-
chromosomal traits are known (OMIM, 16.4.2018). X-linked traits can be
dominant  or  recessive,  but  the  inheritance  pattern  differs  from  that  of
autosomal  traits  because  males  only  have  one  X-chromosome  and  they  are
hemizygous for all X-chromosomal genes. Therefore, X-linked recessive traits
usually  manifest  in  males  only.  X-linked  dominant  traits  manifest  in  both
sexes alike, but they never exhibit male-to-male inheritance.
In  some  cases,  genetic  traits  do  not  seem  to  follow  any  of  the  patterns  of
inheritance described above. Such traits may originate from so-called de novo
mutations. A de novo mutation is a newly arisen mutation that has not been
inherited from either of the parents. Parents who have a child with a de novo
mutation are not at risk of having another child with the same mutation, but
the  child  can  pass  on  the  mutation  to  his/her  own children.  In  some cases,
more than one child in the same family can carry the same apparent de novo
mutation. These mutations are not actual de novo mutations but they are due
to  gonadal  mosaicism  in  one  of  the  parents.  In  gonadal  mosaicism,  the
mutation is present in a proportion of gonadal cells, but not in other cells of
an individual.
Atypical inheritance patterns may also be caused by reduced penetrance.
Penetrance refers to the proportion of individuals harboring a particular
pathogenic mutation or genotype who exhibit clinical signs of the associated
disorder within a specific and clearly defined time period (Cooper et al., 2013).
If  this  proportion  is  not  100%,  the  disorder  is  said  to  exhibit  reduced
penetrance. Reduced penetrance is likely to be a consequence of the
combination of a variety of different genetic and environmental factors. It is
often seen in late-onset diseases in which it can be age-related.
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2.2 Identification of the disease-causing mutation
It  is  very  important  to  identify  the  mutation  responsible  for  any  inherited
disorder.  This  enables  direct  genetic  testing  and  thereby  fast  and  accurate
diagnosis.  When  the  genetic  background  of  a  disease  is  known,  wrong  and
sometimes harmful treatments can be avoided and the patient can be offered
proper management, including genetic counseling, prognosis of the disease,
and possibility to enroll in clinical trials. Curative treatments are not currently
available for most genetic disorders, but some gene therapies have been
developed (Mendell et al., 2017; Mah, 2018), and understanding the genetic
background of the disorders is the first step towards the development of future
therapies.  Identification  of  a  gene  for  a  hereditary  disorder  begins  with
investigating the family history of patients and drawing the pedigrees. Based
on  the  pedigrees,  an  assumption  of  the  mode  of  inheritance  is  made  and
further methods for molecular genetic analyses are selected.
2.2.1 Genetic linkage and linkage analysis
Genetic linkage can be defined as the tendency of DNA sequences located
closely in the chromosome to be inherited together. This means that genes or
other genetic markers that reside close to each other remain linked during
meiosis. In meiosis sister-chromatids exchange homologous segments in a
process called crossing over or recombination. The unit of measurement for
genetic linkage is the centiMorgan (cM). If two loci are 1 cM apart, then a cross-
over  occurs  between  them  in  1  of  100  meioses  (Turnpenny  et  al.,  2005).
Because recombination rarely separates loci that lie very close together, sets of
alleles on the same small chromosomal segment tend to be transmitted as a
block.  Such  a  block  of  alleles  is  known as  a  haplotype  (Strachan  and  Read,
2011).
Linkage analysis is a powerful tool to detect the chromosomal location of
disease genes.  In gene mapping, a panel of genetic markers (microsatellites or
single nucleotide polymorphisms, SNPs) is used to effectively label the
participants’  genomes  so  that  the  segregation  of  genetic  material  can  be
followed. Linkage analysis consists of studying the pattern of co-inheritance of
marker alleles and the presence or absence of a phenotype (Barrett and Teare,
2011). For linkage analysis, a set of recombination fractions and logarithm of
the odds (LOD) scores are calculated. Recombination fraction (θ) is defined as
the frequency with which a single recombination will take place between two
loci in meiosis. If θ = 0, the two loci are in the same genomic position, and if θ
= 0.5,  the  two  loci  are  completely  unlinked.  LOD score  is  a  measure  of  the
likelihood of linkage, which is calculated as follows (Morton, 1955):
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              probability of birth sequence with a given linkage value
           LOD    = log10            probability of birth sequence with no linkage
              (1-θ)NθR
= log10 0,5(N+R)
θ = recombination fraction
N = number of non-recombinant offspring
R = number of recombinant offspring
If LOD ≥ +3, the region is considered to be linked. Linkage can be excluded if
LOD < -2.
The success and reliability of linkage analysis depends on the markers chosen,
the individuals analyzed and the mathematical method used. Microsatellites
are usually highly informative markers because they have many possible
alleles.  SNPs  normally  have  only  two  alleles,  which  means  that  more
informative individuals are needed when using SNPs than when using
microsatellites. However, SNPs are more densely distributed in the genome,
hence providing a means for very high-resolution mapping (Terwilliger et al.,
1992; Barrett and Teare, 2011; Ott et al., 2015).
Linkage analysis can be either parametric or non-parametric. Parametric
linkage  analysis  requires  specification  of  the  mode  of  inheritance,  whereas
non-parametric linkage analysis is model-free (Kruglyak et al., 1996; Barrett
and Teare, 2011). Both can be based on two-point calculations where linkage
is  calculated  between  the  disease  locus  and  the  marker,  or  multipoint
calculations where linkage is calculated between the disease locus and more
than one marker simultaneously (Kruglyak et al., 1996). There are many freely
available  software  packages  for  linkage  analysis  for  different  kinds  of
situations.  Some examples  are  Genehunter  (Kruglyak  et  al.,  1996),  which  is
widely  used  for  non-parametric  linkage  analysis,  Morgan  (Wijsman  et  al.,
2006), which uses Monte Carlo Markov Chain methods and is suited to handle
large complex pedigrees, and Merlin (Abecasis et al.,  2002), which can cope
with very large numbers of marker loci (Barrett and Teare, 2011).
2.2.1.1 Founder effect
In genetically isolated populations derived from a small number of founders,
monogenic disorders may be caused by just one mutation originating from a
single founder. Consequently, in such a population all patients with a certain
disorder share the same mutation as well as the haplotype segregating with the
disorder. Founder effect is a typical phenomenon in the Finnish population,
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particularly  displayed  in  the  Finnish  disease  heritage,  a  group  of  rare
hereditary diseases overrepresented in Finland (Norio et al., 1973; Norio,
2003). In genetically isolated populations, founder effect can be assumed in
linkage analyses,  even though the individuals  analyzed are not known to be
related.
2.2.2 Candidate gene approach
To  identify  a  disease-causing  gene  by  candidate  gene  approach,  a  list  of
possible genes is made. There are many ways to do this. The list can be based
on genes and gene families already identified with similar phenotypes,
knowledge of the protein product compatible with the presumed disease
mechanism, or other hints for possible genes. More often, however, the
chromosomal location of the gene is first defined by linkage analysis, and the
genes within the linked region are listed as candidates. Once the list has been
composed, a search for those genes is made to identify a gene that carries
mutation(s) in patients, but not in controls. For Mendelian conditions, this
approach has been very successful (Strachan and Read, 2011).
2.2.3 Sanger sequencing
Sanger  sequencing  (Sanger  et  al.,  1977)  is  the  conventional  method  for
determining the precise order of nucleotides within a defined DNA region. The
method is based on fluorescently labeled dideoxynucleoside triphosphates
(ddNTPs)  that  randomly  terminate  the  elongation  of  DNA  template.  The
reaction produces a range of different fragments that have a common 5’ end
but variable 3’ ends. The fragments are separated by size using an automated
capillary  sequencer  that  detects  the  fluorescence  of  the  ddNTPs  and
determines the order of the nucleotides.
Sanger sequencing is widely used for mutation detection in both clinical
diagnostics  and research.  However,  the read length in Sanger sequencing is
limited  (usually  500-800  bp),  which  means  that  even  the  smallest  genes
usually have to be sequenced in several parts (Strachan and Read, 2011). This
is  laborious  and  for  large  sequencing  projects  the  method  is  relatively
expensive. The method is also prone to errors; if a primer binding site contains
a  sequence  variation,  there  is  a  risk  of  allele  drop-out.  Therefore,  in  the
absence of heterozygous variants, allele drop-out cannot be excluded (Stevens
et al., 2017).
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2.2.4 Massively parallel sequencing
The  method  of  massively  parallel  sequencing  (MPS),  also  known  as  next-
generation  sequencing  (NGS),  can  carry  out  up  to  billions  of  sequencing
reactions in parallel. There are a number of different MPS platforms (L. Liu et
al.,  2012).  Although they  differ  in  the  underlying  technology  involved,  their
overall processes are very similar: DNA fragmentation, adaptor ligation,
immobilization, amplification, sequencing reaction, and data analysis (Figure
2). Common applications include whole-genome sequencing (WGS), whole-
exome sequencing (WES) or targeted gene panels for disease-causing gene
discovery,  genetic  diagnosis,  and  targeted  cancer  therapy  (Nguyen  and
Burnett, 2014). At least in theory, MPS provides a way to identify a disease-
causing gene without any family data, exact phenotype data, or predefined lists
of candidate genes.
Figure 2. Overview of massively parallel sequencing process.
The  most  commonly  used  platform  for  MPS  is  Illumina.  In  Illumina’s
platform,  DNA  is  fragmented,  e.g.  by  random  shearing  and  adapters  are
ligated  to  the  ends  of  the  fragments.  These  single  molecules  of  DNA  are
attached to a flat  surface (the flow cell)  by hybridizing the adapters to their
complementary sequences on the flow cell. The fragments are amplified in situ
to  form  DNA  clusters.  The  clusters  are  used  as  templates  for  synthetic
sequencing with reversible terminator deoxyribonucleotides labeled with a
removable fluorophore. The sequencing is performed in repeated cycles and
after each cycle of incorporation of nucleotides the identity of the inserted base
is determined by laser-induced excitation of the fluorophores and imaging.
The fluorescent dye of the nucleotides is removed and a 3’ hydroxyl group is
regenerated for the next cycle of nucleotide addition. Images of the surface are
analyzed to generate a high-quality sequence (Bentley et al., 2008).
MPS  enables  sequencing  of  multiple  target  regions  in  one  reaction,  so  that
even the whole human genome can be sequenced in one experiment. This
significantly reduces the costs and time needed for sequencing. MPS also, at
least partly, circumvents the possibility of allele drop-out, as the final sequence
is  compiled  from  multiple  random  fragments  so  that  small  variants  cannot
block out the amplification of the whole allele. There are some limitations in
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MPS as well. Sequencing errors are quite frequent, although they are usually
concentrated  in  certain  (e.g.  GC-rich)  genomic  regions  and  they  may  be
identified using certain quality scores. Incomplete coverage, where regions are
sequenced poorly or not at all, is also a considerable problem. One of the major
challenges  of  MPS  is  data  analysis,  interpretation,  and  storage.  Powerful
computational and bioinformatics tools are required to store the data and
perform  the  various  steps  involved  in  read  alignment,  variant  calling,  and
annotation (Nguyen and Burnett, 2014).
2.2.5 Verification of the mutation
When a possible disease-causing mutation has been identified, its
pathogenicity must be verified. The American College of Medical Genetics and
Genomics (ACMG) and the Association for Molecular Pathology (AMP) have
published standards and guidelines for the interpretation of sequence variants
(Richards  et  al.,  2015).   In  order  to  determine  whether  a  mutation  is
pathogenic,  its  frequency  in  the  general  population  is  ascertained  from
population databases. There are several publicly available population
databases,  some  of  which  are  presented  in  Table  2.  If  the  frequency  of  the
mutation is suitable for the assumed mode of inheritance, the segregation of
the  mutation  with  the  disease  is  studied.  The  possible  consequence  of  the
mutation  may  be  studied  by in silico prediction programs, such as
MutationTaster, PolyPhen or SIFT, but these are not conclusive. Functional
studies  can  be  a  powerful  tool  in  support  of  pathogenicity,  although  not  all
functional  studies are effective in predicting an impact on a gene or protein
function.  According  to  the  guidelines  of  ACMG  and  AMP,  there  is  strong
evidence of the pathogenicity of the mutation if (1) its prevalence in affected
individuals is statistically increased over controls in population databases, (2)
the same amino acid change is an established pathogenic variant or the variant
is predicted to be a null variant in a gene where loss-of-function is a known
disease mechanism, (3) well-established functional studies show a deleterious
effect, and (4) the variant co-segregates with the disease in multiple affected
family members or the variant is confirmed to be de novo.
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Table 2. Examples of publicly available population databases.
Population database Internet address Content
Genome Aggregation
Database, gnomAD
http://gnomad.broadinstitute.org/ The provided data set spans 123 136 exome
sequences and 15 496 whole-genome sequences
from unrelated individuals sequenced as part of
various disease-specific and population genetic
studies. Pediatric disease subjects were excluded.
Exome Variant
Server, EVS
http://evs.gs.washington.edu/EVS Database of variants found during exome
sequencing of more than 200 000 individuals of
European and African American ancestry.
1000 Genomes http://www.internationalgenome.org/ Database of variants found during low-coverage
and high-coverage genomic and targeted
sequencing from 26 populations. Provides more
diversity than EVS, but also contains lower quality
data and some cohorts contain related individuals.
Sequencing Initiative
Suomi, SISu
http://www.sisuproject.fi/ Single-nucleotide variants and insertion/deletions
from exomes of over 10 000 Finns sequenced in
disease-specific and population genetic studies.
2.3 Spinal muscular atrophies
Spinal  muscular  atrophies  are  hereditary  disorders  that  exclusively  or
predominantly  affect  lower  motor  neurons,  leading  to  progressive  muscle
weakness  and  atrophy.  Worldwide  the  most  common  SMA  is  caused  by
mutations in the SMN1 gene on chromosome 5q13. Non-5q SMAs are rare and
both clinically and genetically heterogeneous (Zerres and Rudnik-
Schöneborn,  2003;  Van  Den  Bosch  and  Timmerman,  2006;  Peeters  et  al.,
2014).
2.3.1 SMN1-related SMA
SMN1-related spinal muscular atrophy (SMA1-4, OMIM #253300, #253550,
#253400,  #271150)  is  a  common  autosomal  recessive  disorder  caused  by
degeneration of  anterior horn cells  of  the spinal  cord,  leading to symmetric
muscle  weakness  and  atrophy.  It  is  the  leading  inherited  cause  of  infant
mortality  with a reported incidence of  approximately 1  in 10 000 live births
and a carrier frequency of 1 in 54 (Sugarman et al., 2012). SMN1-related SMA
is  classically  divided  into  four  clinical  subtypes  based  on  the  maximal
functional status achieved (Table 3) (Darras, 2015).
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Table 3. Subtypes of SMN1-related SMA.
SMA type Other name Age at
onset




< 6 months < 2 years Never sits unsupported













Type IV Adult-onset SMA > 21 years Normal Normal
The  disease  is  caused  by  deletions  or  point  mutations  in  the SMN1 gene
(Lefebvre et al., 1995). SMN1 lies  within  an  inverted  duplication  on
chromosome 5q13.  The  centromeric  half  of  the  duplication  contains SMN2,
which  is  an  almost  identical  copy  of SMN1. However, SMN2 differentiates
from SMN1 by  five  nucleotides,  one  of  which  creates  an  exonic  splicing
suppressor that leads to exclusion of exon 7 in almost all transcripts (Monani
et  al.,  1999).  Thus, SMN2 produces  only  a  small  part  of  functional  SMN
protein, and this amount is insufficient to compensate for the loss of function
of SMN1. Patients with mutated SMN1 can carry a variable number of SMN2.
The more SMN2 copies one has, the more SMN protein is expressed and the
less severe the phenotype (Feldkötter et al., 2002; Rudnik-Schöneborn et al.,
2009).
SMN  protein  is  part  of  a  large  multiprotein  complex  and  it  interacts  with
spliceosomal small nuclear ribonucleoprotein particles (Q. Liu et al., 1997).
SMN  plays  a  crucial  role  in  the  generation  of  the  pre-mRNA  splicing
machinery  and  thus  in  mRNA  biogenesis  (Pellizzoni  et  al.,  1998).  SMN
deficiency, similar to that occurring in severe SMA, alters the stoichiometry of
small  nuclear  RNAs  and  causes  widespread  pre-mRNA  splicing  defects  in
numerous transcripts of diverse genes (Z. Zhang et al., 2008).
SMN1-related SMA  is  one  of  the  first  hereditary  disorders  for  which  a
seemingly effective gene therapy has been developed. The first on the market
was  an  antisense  oligonucleotide  drug  nusinersen  (Spinraza),  which  is
administered intrathecally. It binds to SMN2 causing inclusion of exon 7 with
good  effect  when started  early  (Finkel  et  al.,  2017).  The  US Food and  Drug
Administration approved nusinersen for the treatment of patients with all
subtypes  of  SMA  in  December  2016.  However,  the  extreme  cost  of  the
medication and the complicated logistical requirements for administering
nusinersen have raised difficult ethical and health insurance issues (King and
Bishop, 2017).
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2.3.2 Non-5q forms of SMA
Non-5q forms of SMA are usually classified on the basis of inheritance pattern
and  distribution  of  muscle  weakness  (proximal,  distal,  or  bulbar)  (Darras,
2011). The classification of these disorders is difficult, however, because many
genetically defined disease entities show allelic variants and significant
phenotypic overlap,  and,  on the other hand,  one specific  phenotype may be
caused by mutations in more than one gene (Darras, 2011; Rossor et al., 2012).
Despite the growing number of genes implicated in non-5q SMA, no unifying
molecular disease mechanism has been identified. Common pathways to non-
5q  SMA  genes  include  molecular  transport,  lipid  metabolism,  and  RNA
processing and trafficking. It has been hypothesized that large axons of motor
neurons have such high metabolic requirements for maintenance, transport
over long distances, and precise connectivity that they are particularly
vulnerable to defects in ubiquitously expressed proteins (Irobi et al.,  2006).
There  is  significant  clinical  overlap  of  non-5q  SMA  genes  with  other
neuromuscular, mainly neurogenic disorders, such as hereditary spastic
paraplegia, amyotrophic lateral sclerosis, and Charcot-Marie-Tooth disease
(CMT) (Figure 3) (Rossor et al., 2012; Peeters et al., 2014).
Figure 3. Clinical overlap of causal genes for non-5q SMA with other neuromuscular
disorders. Asterisks indicate genes that are also associated with non-neuromuscular
diseases. ALS = amyotrophic lateral sclerosis, CMT = Charcot-Marie-Tooth disease, HSP =
hereditary spastic paraplegia.
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2.3.2.1 Distal spinal muscular atrophy / distal hereditary motor neuronopathy
Distal  spinal  muscular  atrophy  (DSMA),  also  called  distal  hereditary  motor
neuronopathy (dHMN), is a length-dependent, predominantly motor
neuropathy. This is in contrast to CMT and hereditary sensory neuropathies
where sensory involvement is a significant component. The disease is very
slowly progressive and symmetrical, and bulbar involvement is rare (Rossor et
al., 2012). Current classification of OMIM (12.1.2018) uses DSMA for recessive
and  dHMN  for  dominant  forms  of  the  disease.  The  prevalence  of
DSMA/dHMN in Northern England has been reported to be 2.14 per 100 000
(Bansagi et al., 2017).
Increasing numbers of ubiquitously expressed genes have been identified as
the genetic cause of DSMA/dHMN. So far, 15 causative genes and two loci have
been identified (Table 4). The causative genes code for proteins with diverse
functions. For example, HSPB1, HSPB8, and DNAJB2  are chaperones in the
quality control machinery and play a role in regulation of protein folding and
turnover (Carra et al., 2005; Ackerley et al., 2006; Blumen et al., 2012), GARS
and WARS are involved in transfer RNA (tRNA) aminoacylation (Antonellis et
al., 2003; Tsai et al.,  2017), DCTN1 encodes for an axonal transport protein
(Puls  et  al.,  2003),  and  the  protein  product  of ATP7A is  a  cation  channel
(Kennerson et al., 2010). Many of the disease genes are shared between
DSMA/dHMN  and  the  axonal  forms  of  CMT  (CMT2),  indicating  identical
disease mechanisms. Therefore, DSMA/dHMN has been suggested to be a
subcategory of CMT (Bansagi et al., 2017).
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Table 4. Currently known disease genes and loci for distal SMA. Data adapted from OMIM
and GeneTable of Neuromuscular Disorders.
Disease OMIM Inheritance Gene Locus Protein Noteworthy
features




DSMA2 #605726 AR SIGMAR1 9p13.3 Sigma non-opioid
intracellular receptor 1
-
DSMA3 %607088 AR - 11q13.3 - -
DSMA4 #611067 AR PLEKHG5 1p36 Pleckstrin homology
domain-containing
family G member 5
Severe early-
onset
DSMA5 #614881 AR DNAJB2 2q35 DnaJ homolog,
subfamily B member 2
dHMN1 %182960 AD - 7q34-q36 - Juvenile onset












dHMN2D #615575 AD FBXO38 5q32 F-box only protein 38 Calf-predominant
dHMN5A #600794 AD GARS 7p14 Glycine-tRNA ligase Confined largerly
to UL
dHMN5A #600794 AD BSCL2 11q12 Seipin Confined largerly
to UL









dHMN7B #607641 AD DCTN1 2p13 Dynactin subunit 1 Vocal cord
paralysis, facial
paralysis
dHMN9 #617721 AD WARS 14q32 Tryptophan-tRNA
ligase, cytoplasmic
Juvenile onset
dSMAX #300489 XR ATP7A Xq21 Copper-transporting
ATPase 1
-
AR = autosomal recessive, AD = autosomal dominant, XR = X-linked recessive, LL = lower
limbs, UL = upper limbs.
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2.3.2.2 Proximal spinal muscular atrophy
Proximal SMA is  characterized by symmetrical  weakness,  more pronounced
for proximal than distal limb muscles, and generally affecting legs more than
arms. The clinical course ranges from static to rapidly progressive, leading to
respiratory distress requiring mechanical ventilation. Sensitivity is spared
(Peeters et al., 2014). There are also forms of proximal SMA with prominent
additional syndromic features, such as arthrogryposis, myoclonic epilepsy,
sensorineural deafness, or pontocerebellar hypoplasia (Peeters et al., 2014),
but they are not discussed here.
Currently, seven genes are known to cause proximal SMA (Table 5). The most
common form worldwide is SBMA, also known as Kennedy’s disease. SBMA is
a  late-onset  X-linked  recessive  disorder  with  proximal  spinal  and  bulbar
weakness but without pyramidal tract or major sensory impairment (Kennedy
et  al.,  1968).  Its  prevalence  in  the  Vaasa  region  of  Western  Finland  was
estimated to be 13 per 85 000 male inhabitants (Udd et al., 1998), but has later
been  shown  to  be  two  times  more  common  (Bjarne  Udd,  personal
communication). SBMA is caused by a repeat-expansion mutation in the first
exon of the AR gene (La Spada et  al.,  1991).  This study concerns the eighth
subtype of proximal SMA.
As  with  distal  SMAs,  the  causative  genes  of  proximal  SMAs  are  mostly
ubiquitously expressed. The protein products of LMNA are lamin A and lamin
C, which are structural  components of  the nuclear lamina (Stuurman et  al.,
1998), whereas TRPV4 encodes for a cation channel (Deng et al., 2010), and
DYNC1H1 and BICD2 produce molecular motors (Harms et al., 2012; Neveling
et al., 2013; Oates et al.,  2013; Peeters et al.,  2013). Their molecular defects
can  affect  also  other  tissues,  causing  e.g.  diverse  laminopathies  (LMNA),
skeletal dysplasias (TRPV4),  and  malformations  of  cortical  development
(DYNC1H1) (Peeters et al., 2014).
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Table 5. Currently known disease genes for proximal non-5q SMA. Data adapted from
OMIM and GeneTable of Neuromuscular Disorders.
Disease OMIM Inheritance Gene Locus Protein
Scapuloperoneal
SMA
#181405 AD TRPV4 12q24.11 Transient receptor
potential cation channel






























#313200 XR AR Xq12 Androgen receptor
2.3.2.3 Spinal muscular atrophy, Jokela type
Spinal  muscular  atrophy,  Jokela  type  (SMAJ,  OMIM  #615048),  originally
named  late-onset  spinal  motor  neuronopathy  (Jokela  et  al.,  2011),  is  a
relatively benign form of autosomal dominant SMA identified and described
in several Finnish families. The disease onset is after the age of 30-40 years,
and  it  is  characterized  by  painful  cramps  and  fasciculations  affecting  the
proximal and distal muscles of the upper and lower limbs. Other symptoms
and signs of the disease are decreased or absent tendon reflexes, elevated
creatine kinase (CK), and hand tremor. The disease is slowly progressive,
resulting  in  weakness  and  mild  to  moderate  muscle  atrophy  later  in  life.
Patients have remained ambulant for several decades after onset of the disease
and  their  life  expectancy  is  within  normal  range.  Electromyography  and
muscle  biopsy  reveal  chronic  and  active  neurogenic  findings  (Jokela  et  al.,
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2011;  Jokela,  2015).  So  far,  the  disease  has  not  been  reported  in  other
populations.
2.4 CHCHD10
CHCHD10 is a gene located on chromosome 22: 23,765,834-23,768,443
(reference sequence GRCh38.p10). CHCHD10 has four exons and it encodes
for five transcripts, three of which are potentially protein coding (Figure 4).
The gene has one paralogue, CHCHD2, and 79 known orthologes throughout
the  animal  kingdom,  including  invertebrates.  The  genomic  sequences  of
CHCHD2 and CHCHD10 are approximately 54% identical (Ensembl genome
browser 91) (Zerbino et al., 2018).
Figure 4. Human CHCHD10 gene. The gene is located on the reverse strand at 23,765,834-
23,768,443. Different splice variants are marked with light green background. Open boxes
indicate non-coding regions of each transcript. NMD = nonsense mediated decay. Data
adapted from Ensembl.
2.4.1 Structure and function of CHCHD10 protein
CHCHD10 encodes a coiled-coil-helix-coiled-coil-helix (CHCH) domain
containing protein. CHCHD10 belongs to a family of mitochondrial proteins
characterized by two conserved CX9C motifs, called twin CX9C proteins. The
CHCH domain forms a helix-turn-helix fold, stabilized by two disulfide bonds
(Cavallaro,  2010).  The  exact  structure  of  CHCHD10  is  not  known,  but  a
prediction, modeled with RaptorX structure prediction server (Källberg et al.,
2012), is presented in Figure 5.
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Figure 5. Predicted structure of CHCHD10. A. Predicted tertiary structure of CHCHD10.
Secondary structures are colored. B. Schematic presentation of CHCHD10 domains.
Numbers refer to amino acids. MTS = mitochondrial targeting sequence.
The  function  of  CHCHD10 remains  unknown.  It  has  been  established  to  be
located  in  the  intermembrane  space  of  mitochondria  and  to  be  enriched  at
cristae junctions (Bannwarth et  al.,  2014).  CHCHD10 is  associated with the
mitochondrial inner membrane, through either a transmembrane helix or a
membrane-bound region (Burstein et al., 2018). CHCHD10 has been reported
to  be  part  of  the  mitochondrial  contact  site  and  cristae  organizing  system
(MICOS)  complex  (Genin  et  al.,  2015),  which  is  crucial  for  mitochondrial
membrane architecture and cristae organization (Rampelt et al., 2017).
However,  in another study,  the association of  CHCHD10 with MICOS could
not be shown (Straub et al., 2018). Furthermore, no ultrastructural
abnormalities  of  mitochondria  were  detected  in  CHCHD10  knockout  mice
(Burstein  et  al.,  2018)  or  in  patient-derived  fibroblasts  (Brockmann  et  al.,
2018;  Straub  et  al.,  2018),  which  does  not  support  the  hypothesis  that
CHCHD10 is required for mitochondrial cristae maintenance (Burstein et al.,
2018).
Two recent independent studies suggest that CHCHD10 interacts with
CHCHD2,  both  of  which  interact  with  p32/C1QBP,  a  protein  with  various
intra- and extra-mitochondrial functions (Burstein et al., 2018; Straub et al.,
2018).  There  is  also  evidence  that  CHCHD10-CHCHD2  complexes  are
necessary for efficient mitochondrial respiration (Burstein et al., 2018; Straub
et  al.,  2018),  and  the  results  of  Straub  et  al.  (2018)  suggest  a  key  role  for
CHCHD10 in respiration, particularly under the stress conditions induced by
forcing mitochondrial oxidative phosphorylation and increasing oxidative
stress. CHCHD10 and CHCHD2 both have rapid turnover, supporting
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regulatory rather than structural function (Burstein et al., 2018). A study
utilizing Caenorhabditis elegans models,  mouse  cell  lines,  mouse  primary
neurons and mouse brains, demonstrated that CHCHD10 exerts a protective
role in mitochondrial and synaptic integrity and inhibition of cytoplasmic
TDP-43  accumulation  (Woo  et  al.,  2017).  However,  in  patient-derived
fibroblasts TDP-43 mislocalization could not be detected, and the results
demonstrated that mutant alleles CHCHD10R15L and CHCHD10G66V are  not
expressed  in  patient  cells  (Brockmann  et  al.,  2018).  CHCHD10  knockdown
studies in different cell lines have contradictory results, suggesting that there
could be a cell type specificity involving compensatory processes for the loss of
CHCHD10 (Burstein et  al.,  2018).  The effect  of  mutant CHCHD10 has been
speculated  to  cause  disease  through  a  gain  of  toxic  function  mechanism
(Burstein et al., 2018) or haploinsufficiency (Woo et al., 2017; Brockmann et
al., 2018; Straub et al., 2018).
2.4.2 Diseases associated with mutations in CHCHD10
Dominant mutations in CHCHD10 have been identified to cause a wide range
of neurological disorders. The first reported mutation was c.176C>T p.S59L,
described to cause frontotemporal dementia (FTD)-ALS with mitochondrial
myopathy (Bannwarth et al., 2014). Two mutations, c.43C>A p.R15S and
c.172G>C p.G58R, located in cis have  been  identified  as  a  cause  of
mitochondrial  myopathy  (Ajroud-Driss  et  al.,  2015).  In  addition  to  these
distinct phenotypes, several CHCHD10 mutations have been associated with
different neurological disorders, including ALS, FTD, Alzheimer’s disease, and
Parkinson’s disease (Table 6). Most of the reported patients have been
sporadic cases and no segregation studies have been available. Functional
studies have shown that mutations p.R15L, p.G58R, p.S59L, and p.G66V alter
the protein function (Bannwarth et al., 2014; Ajroud-Driss et al., 2015; Woo et
al., 2017; Brockmann et al., 2018; Burstein et al., 2018; Straub et al., 2018),
whereas other potentially pathogenic mutations have not been investigated at
protein level so far.
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Table 6. Possibly pathogenic exonic variants in CHCHD10. Data concerning mutation
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2 Italy, China n.a. n.a. (M. Zhang et al.,






































2 0,0002869 ALS 4 Italy,
Canada,
Belgium



















3  - FTD 1 Belgium n.a. n.a. (Perrone et al.,
2017)
The variants have been annotated according to transcript NM_213720. AD = Alzheimer’s
disease, ALS = amyotrophic lateral sclerosis, CMT2 = Charcot-Marie-Tooth disease type 2,
MM = mitochondrial myopathy, FTD = frontotemporal dementia, FTLD = frontotemporal
lobar degeneration, PD = Parkinson’s disease, SMAJ = spinal muscular atrophy, Jokela type,
n.a. = not assessed, * = mutations in cis, † = homozygous muta on.
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3 AIMS OF THE STUDY
This work was the genetic  part  of  a  larger study aiming at  describing a new
disease entity both clinically and genetically. Prior to this thesis work, it had
long been known that there are Finnish patients with an autosomal dominant,
adult-onset lower motor neuron disease that does not really fit any previously
defined neuromuscular disease categories. The study started already in 2008,
and the first clinical paper was published in 2011 (Jokela et al., 2011).
The aims of this study were as follows:
1. To show that late-onset spinal motor neuronopathy is a new, genetically
distinct entity.
2. To provide evidence for a possible founder mutation.
3. To identify the disease-causing mutation.
4. To investigate Finnish neuromuscular disease patients to determine the
prevalence and clinical outcome of the mutations in the identified gene
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4 SUBJECTS AND METHODS
4.1 Patients and controls
In this study, altogether 437 DNA samples from patients and unaffected family
members were included. A summary of all samples is presented in Table 7. The
DNA was isolated from peripheral blood leukocytes or saliva. All individuals
included in the study were adults and all unaffected family members were at
least  35  years  old.  The  age  of  affected  individuals  at  clinical  examination
ranged from 29 to 86 years. All individuals were of Finnish origin, although
two  blood  samples  were  provided  from  Sweden.  In  addition,  104  control
samples from the normal Finnish population were used.
This study was conducted at Tampere Neuromuscular Research Center. The
study  protocol  was  approved  by  local  ethics  committees,  and  samples  were
obtained in accordance to the Declaration of Helsinki.
Table 7. Summary of the samples used in the study.






Study I 11 - 7 - -
Study II 43 7 11 5 -
Study III 18 37 11 19 104
Study IV 336 - - - -
Total 408 29 104
4.1.1 Linkage analysis (I)
Samples included in Study I were collected from members of two families (F1
and F2) initially identified and evaluated clinically (Jokela et al., 2011). DNA
samples of 18 individuals were investigated. Eleven individuals were affected,
six were unaffected, and the affection status of one family member was
uncertain.
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4.1.2 Identification of new families and refinement of the linked region (II)
Patients included in Study II were adult sporadic SMA patients and patients
in families with autosomal dominant inheritance and a phenotype compatible
with SMAJ (e.g. slowly progressive lower motor neuron disease, absent tendon
reflexes, elevated CK). DNA samples were collected from 54 individuals
belonging to 26 families. Eleven of these individuals were unaffected family
members. In addition, the DNA samples of 12 members (seven affected, five
unaffected) of family F1 from Study I were included in the analyses.
4.1.3 Identification of the disease-causing mutation (III)
Study  III  included  55  patients  and  30  unaffected  family  members  from  17
families with adult-onset SMA and autosomal dominant inheritance. The DNA
samples of  56 individuals  had already been included in Studies I  and/or II,
whereas 29 DNA samples were new. In this study, also 104 anonymous control
DNA samples were used. The control samples had been obtained from Finnish
blood donors originally collected for the ‘Health 2000 Project’ in collaboration
with Professor Leena Peltonen-Palotie.
4.1.4 Prevalence and clinical outcome of CHCHD10 mutations in Finland (IV)
In  Study  IV,  336  Finnish  patients  with  distinct  neurogenic  disorders  were
selected to clarify whether CHCHD10 mutations are prevalent in selected
disease  groups.  Of  these  patients,  215  had  lower  motor  neuron  syndrome
similar  to  SMAJ,  28  had  hereditary  spastic  paraplegia  (HSP),  24  had  non-
specified neurogenic disorder, 14 had mitochondrial myopathy, and 55 had a
diagnosis of ALS.
4.2 Methods
4.2.1 DNA isolation (I-IV)
Genomic DNA was isolated from peripheral blood and muscle biopsies using
Puregene  DNA  Blood  Kit  (Gentra  Systems,  Minneapolis,  MN,  USA)  or
ArchivePure DNA Purification Kit (5 Prime, Hamburg, Germany). From saliva
samples,  DNA  was  isolated  using  Oragene  DNA  saliva  kits  (DNA  Genotek,
Ottawa, Canada) according to the manufacturer’s instructions.
37
4.2.2 Genotyping (I-III)
For 16 members of  families F1 and F2,  a  genome-wide scan was performed
using  deCODE 536  microsatellite  marker  set  at  an  average  of  8  cM density
(Kong  et  al.,  2002).  To  confirm  and  refine  the  haplotype,  seven  additional
microsatellite markers, D22S264, D22S446, D22S306, D22S686, D22S926,
D22S419, and D22S421, were analyzed in Study I. In Study II, six more
microsatellite markers (D22S303, SHGC-106816, D22S301, D22S345,
D22S343, and D22S925) were added so that up to 13 microsatellite markers
were used for genotyping. The fluorescently labeled polymerase chain reaction
(PCR)  products  were  analyzed  using  ABI3130xl  automatic  DNA  Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA) and Peak Scanner
Software v1.0 (Applied Biosystems).
4.2.3 Linkage analysis (I) and haplotype construction (I-III)
Linkage analysis on all autosomes was run with Merlin (Abecasis et al., 2002)
using  the  results  of  the  genome-wide  scan  and  genotyping  of  markers
D22S264, D22S446, D22S306, D22S686, D22S926, D22S419, and D22S421.
In linkage analysis, a parametric dominant model was used with a disease
allele frequency of 0.0001 and absolute disease risk of 0.9 for carriers. In Study
I, haplotypes were constructed using Merlin. In later studies (II, III),
haplotypes were constructed manually referring to the founder haplotype.
4.2.4 Exome sequencing (II)
Exome  sequencing  was  performed  at  the  Axeq  Technologies  laboratory  in
South Korea. The DNA enrichment was performed using Illumina TruSeqTM
Exome  Enrichment  Kit  (Illumina,  San  Diego,  CA,  USA).  Captured  DNA
fragments  were  sequenced  on  Illumina  HiSeq  2000  platform  using  100  bp
paired-end reads. Sequence reads were aligned to the human reference
genome (UCSC hg19) using Burrows-Wheeler Aligner (H. Li and Durbin,
2009),  and  variant  calling  was  carried  out  with  Genome  Analysis  Toolkit
(GATK; Broad Institute, Cambridge, MA, USA). Bioinformatics was performed
at Axeq Technologies. The data were visualized with Integrative Genomics
Viewer (Robinson et al., 2011; Thorvaldsdottir et al., 2013).
4.2.5 Sanger sequencing (II-IV)
Sanger sequencing was performed in Study II for the entire coding sequence
of the two best candidate genes at the linked region, SNRPD3 and SGSM1. In
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Study III, exon 8 in SLC2A11 and exon 2 in CHCHD10 were sequenced in three
patients (F1:II-16, F6:II-3, and F12:II-2) to verify the potential disease-causing
variants found in WGS and to determine whether the variants segregate with
the  disease.  Exon  2  in CHCHD10 was  then  sequenced  in  all  subjects  in  the
study.  In  Study  IV,  exon  2  in CHCHD10 was  sequenced  in  all  patients.
Additionally, in 103 patients, the rest of the coding region was also sequenced
in order to detect possible mutations outside exon 2.
Primer sequences for the exons studied were designed using Primer3 software
(Koressaar and Remm, 2007; Untergasser et  al.,  2012) to include the entire
exon and exon-intron borders. The regions examined were amplified with PCR
(DyNAzyme  II,  Thermo  Scientific  Finnzymes,  Vantaa,  Finland  or  Thermo
Scientific  Fermentas  PCR Master  Mix;  MBI  Fermentas,  Amherst,  NY,  USA)
and directly sequenced using a Big-Dye Terminator v3.1 Kit on an ABI3130xl
automatic DNA Genetic Analyzer (Applied Biosystems). Sequences were
analyzed with Sequencher 5.1 software (Gene Codes Corporation, Ann Arbor,
MI, USA).
4.2.6 Whole-genome sequencing (III)
The DNA sample of patient F1:II-16 was used for whole-genome sequencing.
WGS was performed at Beijing Genomics Institute (BGI) using the Illumina
HiSeq 2000 platform (500 bp library, 90 bp paired-end reads), resulting in at
least 30X haploid coverage. Genome was aligned to hg19 reference genome
with Burrows-Wheeler Aligner (H. Li and Durbin, 2009). SNPs were detected
by SOAPsnp (R.  Li  et  al.,  2009),  small  insertion/deletions were detected by
SAMtools  (H.  Li  et  al.,  2009),  and  structure  variants  were  identified  by
BreakDancer/CREST (Chen et al., 2009). ANNOVAR (Wang et al., 2010) was
used to annotate the variant results. Bioinformatics was performed at BGI. The
whole linked region (chr22: 23,761,389-24,488,587) was visualized and
manually  inspected  by  Integrative  Genomics  Viewer  (Robinson  et  al.,  2011;
Thorvaldsdottir et al., 2013).
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5 RESULTS AND DISCUSSION
5.1 Linkage analysis (I)
Study  I  included  two  families,  F1  and  F2,  which  had  already  been  clinically
described (Jokela et al., 2011). In the study of Jokela et al. (2011) linkage to all
chromosomal loci for hereditary motor neuropathies known at that time had
been excluded. However, without further genetic evidence it was still uncertain
if the disease in the two families was the same and if it really was a new type of
SMA. In the genome-wide scan of Study I, significant linkage was obtained on
chromosome 22q11.2-q13.2, the maximum LOD being 3,43 at marker
D22S315.  This  confirmed  that  the  disease  in  F1  and  F2  was  a  genetically
distinct entity.
The linked region was defined by flanking markers D22S686 and D22S276,
comprising 18.9 Mb. None of the 402 genes located in the linked region were
previously  known  to  be  associated  with  SMAs.  Unfortunately,  most  of  the
genes inside the linked area were poorly described, and there were no obvious
candidate genes. On the other hand, because the genes known to cause motor
neuron disorders have highly variable functions, practically no genes could be
excluded.
The disease-associated haplotype (Figure 6A) was identical in both families.
This provided evidence for a common founder mutation. The families were not
known to be related, but they both originated from Northern Karelia, which
belongs to the area of late settlement in Finland, populated in the 1500s and
thereafter. In this region, the population started to expand only 15-25
generations ago from a small group of founders (Norio, 2003). Therefore, it
was reasonable to assume that F1 and F2 should have a common ancestor, and
because the disease was dominantly inherited, it was likely that more Finnish
patients with the same linked haplotype could be identified.
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Figure 6. Disease-associated haplotype. A. The founder haplotype identified in families F1
and F2 in Study I. The markers shown in boldface were part of the deCODE 536
microsatellite marker set. B. Informative recombinations found in Study II (F6:III-3 and
F7:III-15) and Study III (F12:I-2). F7:III-15 is unaffected, other individuals presented are
affected. The founder haplotype is shown in gray.
5.2 Identification of new families and refinement of the linked region (II)
The disease-associated haplotype identified in Study I enabled a screening
study  based  on  a  founder  effect  hypothesis.  In  Study  II,  genotyping  of  the
linked  area  was  performed  for  a  cohort  of  patients  with  late-onset  SMA  or
undetermined lower motor neuron disease. Altogether 26 patients from nine
new families were identified to carry the disease-associated haplotype. The
expanded cohort  of  SMAJ patients enabled more accurate determination of
the phenotype and diversification of  the characteristics  of  SMAJ disease.  At
this point, the number of SMAJ patients was already 37, indicating that the
prevalence of SMAJ could be quite high in Finland. Our results suggested that
the  point  prevalence  of  SMAJ  in  Northern  Karelia  (12:100  000  with  these
patient numbers) already exceeded that of ALS.
The identification of new patients confirmed the founder hypothesis.
Especially in diseases belonging to the Finnish disease heritage, strong linkage
disequilibrium between disease gene and nearby markers is a rule (Norio,
2003),  which seems to be the case in SMAJ as well.  The results  of  Study II
showed that the founder haplotype could be used to genetically identify SMAJ
patients,  at  least  when enough family members are available to confirm the
segregation of the markers. A genotyping test for SMAJ disease based on the
founder  haplotype  was  indeed  used  in  clinical  diagnostics  for  some time  at
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Tampere Neuromuscular Research Center before the disease-causing gene
was identified.
There were significant recombinants in the new patient cohort (F6:III-3 and
F7:III-15, Figure 6B), which restricted the disease locus by 90% to 1.8 Mb. The
refined region was located between markers SHGC-106816 and D22S343 and
included 55 genes. To identify the disease-causing gene, we performed WES
using the samples of four affected patients and two healthy family members.
Surprisingly, however, WES did not reveal any potentially pathogenic variants
that would have segregated with the disease. This was due to very low coverage
at the linked region; over 60% of exons were covered poorly (< 10X) or not at
all.  Retrospectively,  this  kind  of  methodological  limitation  of  WES  was  not
uncommon at that time.
After  unsuccessful  WES,  we  selected  two  candidate  genes  with  the  most
potential, SNRPD3 and SGSM1, for Sanger sequencing. SNRPD3 encodes for
small nuclear ribonucleoprotein Sm D3 (snRNP Sm-D3), which interacts with
SMN (Friesen and Dreyfuss, 2000). SGSM1,  in turn, is thought to modulate
the small G protein RAP and RAB-mediated neuronal signal transduction and
vesicular  transport  pathways  (Yang  et  al.,  2007).  Both  are  thus  related  to
neuronal functions, and mutations in these genes could cause neurological
disease. However, no mutations in either SNRPD3 or SGSM1 were found, and
the disease-causing gene was left unidentified. Diseases caused by mutations
in SNRPD3 or SGSM1 are still not known.
5.3 Identification of the disease-causing mutation (III)
By the time of Study III, we had identified altogether 55 SMAJ patients from
17 families by genotyping. In family F12, a new informative recombination was
observed  (Figure  6B)  that  reduced  the  linked  region  to  727  kb  between
markers SHGC-106816 and D22S345. Because WES in Study II had failed and
there  were  no  more  good  candidate  genes  left,  we  performed  WGS  for  one
patient (F1:II-16). Inspection of the coding areas of the linked region revealed
two heterozygous candidate mutations that were absent from the Exome
Variant  Server  and  1000 Genomes  databases.  These  were  a  silent  mutation
c.728C>T in SLC2A11 and  a  missense  mutation  c.197G>T  p.G66V  in
CHCHD10.
Sanger sequencing of exon 8 in SLC2A11 and exon 2 in CHCHD10 verified that
both variants seen in WGS were true findings, but only c.197G>T p.G66V in
CHCHD10 segregated with the disease. The pathogenicity of c.197G>T p.G66V
was supported by the finding that it was present in all 55 SMAJ patients and
absent from unaffected family members as well as from 104 Finnish normal
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population control  samples.  The mutated glycine residue G66 is  completely
conserved  in  CHCHD10  orthologs,  suggesting  that  it  is  intolerant  to
mutations.
During Study III the first disease associated with CHCHD10 was reported.
Dominant mutation c.176C>T p.S59L was described to cause FTD-ALS with
mitochondrial myopathy (Bannwarth et al., 2014). Soon afterwards,
CHCHD10 allele  c.[43C>A;172G>C]  p.[R15S;G58R]  was  reported  to  cause
mitochondrial  myopathy  (Ajroud-Driss  et  al.,  2015),  and  mutation c.44C>A
p.R15L was described to be associated with ALS (Johnson et al., 2014; Müller
et al., 2014). Also c.197G>T p.G66V was reported by Müller et al. (2014) in one
of our Finnish patients described as having slowly ascending progressive
motor neuron disease. The phenotype of this patient (F16:III-1) was described
in  detail  in  Study  III.  Expression  studies  showed  that  cells  expressing
CHCHD10S59L, CHCHD10R15S/G58R, and CHCHD10G58R undergo fragmentation
of  the  mitochondria  (Bannwarth  et  al.,  2014;  Ajroud-Driss  et  al.,  2015).
Because amino acid G66 resides at the same evolutionarily conserved region
encoding  for  a  highly  hydrophobic  helix  as  S59  and  G58,  these  results
supported the pathogenic role of the c.197G>T p.G66V mutation.
Functional studies of the pathogenic mechanism of the p.G66V mutation were
not  performed until  very  recently  (Brockmann et  al.,  2018).   In  their  study
using patient fibroblasts, Brockmann et al. (2018) showed that with regard to
the CHCHD10 p.G66V mutant, altered secondary structure and rapid protein
degradation were observed. Their results of further indicated that p.G66V, as
well  as  p.R15L,  causes  a  reduction  of  CHCHD10  protein  levels  in  mutant
patient fibroblasts to approximately 50%, and hence, their pathogenicity was
suggestive of haploinsufficiency of CHCHD10. However, in muscle biopsies of
SMAJ patients, mitochondrial CHCHD10 was shown to be normally expressed
in immunohistochemistry, and mitochondria were also ultrastructurally
normal (Jokela et al., 2016).
The results of Study III show that heterozygous mutation c.197G>T p.G66V in
CHCHD10 is the cause of SMAJ. CHCHD10 was the first SMA-causing gene
identified  that  codes  for  a  mitochondrial  protein.  The  phenotype  of  SMAJ
differs significantly from other reported CHCHD10-related phenotypes (FTD-
ALS with mitochondrial myopathy, mitochondrial myopathy, ALS), showing
that,  as  with  other  SMA-causing  genes,  also CHCHD10 may cause highly
variable phenotypes.
5.4 Prevalence and clinical outcome of CHCHD10 mutations in Finland (IV)
The results of Study III suggested that the prevalence of SMAJ in Finland is
considerable. On the other hand, it seemed possible that mutation c.197G>T
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p.G66V could cause other phenotypes besides SMAJ. Already one study had
reported  c.197G>T p.G66V to  cause  CMT2 (Auranen  et  al.,  2015),  although
three patients in that study had already been published in our previous studies
(F1:III-27, F14:II-1, F14:II-2) and their phenotype was typical SMAJ without
sensory  abnormalities  compatible  with  CMT2.  In  another  family,  c.197G>T
p.G66V had been reported to cause intrafamilial clinical variability ranging
from SMAJ to CMT2 (Pasanen et al., 2016). Study IV was performed in order
to clarify the presence of different CHCHD10 mutations  as  well  as  their
phenotypic manifestations in Finland.
In  Study  IV,  we  screened  several  cohorts  of  Finnish  patients  with  distinct
neurogenic disorders and one cohort of mitochondrial myopathy, a total of 336
patients with undetermined disease. The mutation c.197G>T p.G66V was
found in 23 patients, all of whom had a phenotype restricted to SMAJ.
Together with the results of Study IV, the number of all reported patients
carrying c.197G>T p.G66V was now 93, suggesting that c.197G>T p.G66V is a
common mutation in Finland.
In the Sequencing Initiative Suomi database (SISu, 25.1.2018) the variant
c.197G>T p.G66V was present in 4/9415 individuals. Thus, allele frequency of
the mutation would be 0.000212427 in the Finnish population.  Notably,  all
four mutation carriers in SISu are from Northern Karelia. In SISu, the same
person might appear multiple times and persons may be related to each other.
Therefore, the allele frequency of c.197G>T p.G66V may be overestimated. On
the basis of our determined patients and the SISu frequency, we estimate the
prevalence  of  c.197G>T  p.G66V  to  be  around  4/100  000  in  Finland.
Considering  the  age  of  onset,  this  prevalence  suggests  altogether  some 200
symptomatic SMAJ patients in Finland.
No other possibly pathogenic mutations were found in any of the cohorts, not
even in those 103 patients for whom the whole coding region of CHCHD10 was
sequenced. These results support the impression that pathogenic mutations in
CHCHD10 are concentrated in exon 2. Only one mutation in exon 1 and three
mutations in exon 3 have been reported (Dols-Icardo et al., 2015; Perrone et
al., 2017; Q. Zhou et al., 2017), but their pathogenicity is unclear. According to
our results, possible other CHCHD10 mutations, if present at all, have to be
extremely rare in the Finnish population.
There  is  growing  evidence  that  dominantly  inherited  mutations  in  SMA-
causing  genes  may  also  cause  CMT2.  At  least  mutations  in HSPB1, HSPB8,
and DYNC1H1 do not cause distinct entities but a continuum of phenotypes
ranging  from SMA to  CMT2 (Solla  et  al.,  2010;  Hoffman and  Talbot,  2012;
Bombelli et al., 2014). It is notable that MFN2, a well-described mitochondrial
protein-coding gene, also causes very heterogeneous clinical features.
Mutations in MFN2 primarily cause type 2A CMT, but a continuum between
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CMT2 and dHMN has been suggested (Bombelli et al., 2014). These results are
supported by a recent study by Bansagi et al. (2017) who suggest that dHMN
should  be  included  as  a  subcategory  of  CMT.  It  is  debatable  whether  all
patients  carrying  c.197G>T  p.G66V  have  typical  SMAJ  or  whether  the
phenotype extends into the category of CMT2. Nevertheless, SMAJ is an
important differential diagnostic alternative in patients with a neurogenic
disorder suggestive of  CMT2 or even ALS because patients with SMAJ have
received both of these diagnoses before the final molecular diagnosis.
In general, CHCHD10-related disorders seem to be rare worldwide (Table 6).
Of the ascertained CHCHD10-related  disorders,  SMAJ  is  by  far  the  most
frequent. This is due to the enrichment of the founder mutation in the Finnish
population.  Based  on  the  genotype  studies,  it  is  evident  that  all  Finnish
patients  carrying  the  mutation  c.197G>T  p.G66V  have  a  common  ancestry,
probably  of  Northern  Karelian  origin  (Figure  7).  DMLE+  Linkage
disequilibrium mapping software (Rannala and Bertorelle, 2001) estimates
that our genotyped families had a common ancestor approximately 4-5
generations  ago  (unpublished  data).  This  estimation  is  not  very  accurate,
however, because the allele frequencies of the employed markers in the normal
population are not known. In any case, it is possible that c.197G>T p.G66V is
a relatively recent mutation in the Finnish population.
Figure 7. Number of SMAJ patients by Finnish hospital districts found in Studies I-IV (total
78). Two patients were living in Sweden and are not shown on the map. Northern Karelia is
indicated in red.
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5.5 Limitations and methodological considerations
Although the goals of this work were achieved, there are some limitations of
the studies. Considering the number of patients and families available it took
a very long time to identify the disease-causing gene. One reason for this was
the lack of informative recombinations. The recombination in family F12 that
restricted the linked region to 727 kb and 22 genes was only identified after
Study II. This hindered the selection of potential candidate genes for
sequencing. On the other hand, CHCHD10 was reported to cause neurological
disease only after the SMAJ-causing mutation was identified. Besides,
CHCHD10 was  the  first  SMA-causing  gene  known  to  encode  for  a
mitochondrial  protein,  and  based  on  its  function  it  would  have  been  an
unlikely candidate, no matter how short the gene list would have been.
From  the  WES  data,  the  disease-causing  mutation  should  have  been  easily
found, especially with the number of patients that we used (four affected, two
unaffected). However, the quality of our WES data was too poor so that most
of the linked area was insufficiently covered. At the time of Study II (in 2012-
2013), WES was still a new method and the quality of produced data was highly
variable. It was unfortunate that the quality of our WES run was low. However,
according to gnomAD CHCHD10 is still a difficult gene for WES so that even
with  the  present  WES methods  the  coverage  of CHCHD10 is often too low.
Possibly  we  might  have  identified  c.197G>T  p.G66V  by  rerunning  WES  or
adding more sequencing cycles to the original WES, but WGS was probably a
more certain method.
Another shortcoming of this study was that functional studies for mutation
c.197G>T p.G66V were not performed. Because CHCHD10 was not a known
disease-causing gene when we identified the mutation, we planned for in vivo
studies in zebrafish. However, before the zebrafish studies were started the
first CHCHD10-related  disease  was  published.  The  first  publication  was
followed by numerous letters reporting new CHCHD10 mutations, which
made us hasten the publication of our finding and abandon the planned
zebrafish studies. Hence, according to the guidelines of ACMG and AMP the
evidence for the pathogenicity of c.197G>T p.G66V is not yet classified as very
strong (Richards et al., 2015). The final evidence for the pathogenicity as well
as solving the pathomechanism of c.197G>T p.G66V were left for future
studies.
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6 CONCLUSIONS AND FUTURE PROSPECTS
This study showed that SMAJ is a genetically distinct previously unknown
entity,  caused  by  a  dominant  mutation  c.197G>T  p.G66V  in CHCHD10.
According  to  genotyping  results  c.197G>T p.G66V is  a  founder  mutation  in
Finland, all SMAJ patients having common ancestry. SMAJ fulfills the criteria
of being part of the Finnish disease heritage; it is a rare hereditary disease that
is relatively common in Finland and according to present knowledge, totally
absent from other populations. The origin of SMAJ seems to be in Northern
Karelia,  suggesting  that  the  mutation  was  introduced  in  the  Finnish
population quite recently. Genealogical studies might refine the estimation of
the age of the mutation.
In  Finland,  with  possibly  as  many  as  200 patients,  SMAJ may  be  the  most
common  form  of  SMA,  its  prevalence  exceeding  even  that  of SMN1-related
SMA. This study enabled genetic testing of SMAJ, which is of great importance
for  the  patients  in  order  to  provide  them  with  an  accurate  diagnosis  and
prognosis. Many SMAJ patients had initially received a diagnosis of ALS,
which  carries  a  much  grimmer  prognosis  than  SMAJ.  At  the  Tampere
Neuromuscular Research Center, 101 SMAJ patients had been genetically
diagnosed by January 2018 (unpublished data). This number represents only
a  proportion  of  the  Finnish  SMAJ  patients  because  genetic  testing  for
CHCHD10 is  nowadays  offered  also  in  other  laboratories  and  totally  new
families  are  still  identified.  Thus,  SMAJ  seems  to  be  the  most  common
CHCHD10-related disease in the world.
Notably,  also  one  patient  homozygous  for  c.197G>T  p.G66V  has  been
identified (unpublished data). The phenotype of the homozygous patient is
very similar to SMAJ, albeit much more severe. The onset of the disease was
already in childhood and at the age of 36 years the patient became wheel-chair
bound. The parents of the homozygous patient both belong to known SMAJ
families and have a typical SMAJ phenotype (Manu Jokela, personal
communication).  This patient is  the first  individual  globally  known to carry
confirmed pathogenic CHCHD10 mutations on both alleles.
To date, SMAJ seems to be an exclusively Finnish disease. Two patients of this
study live in Sweden and it is very possible that there are more SMAJ patients
of Finnish descent outside Finland. Also non-Finnish SMAJ patients may
exist, but studies performed thus far have not been able to identify them.
According to gnomAD (25.1.2018), mutation c.197G>T p.G66V has no
frequency in non-Finnish populations. However, population databases do not
contain data from all populations and, for example, the Russian population is
underrepresented. This is unfortunate because it is likely that c.197G>T
p.G66V is present in Russian Karelia.
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Although c.197G>T p.G66V has not been seen in non-Finnish populations, a
mutation in an adjacent nucleotide affecting the same amino acid, c.196G>A
p.G66S, has been detected in eleven European (non-Finnish) individuals (total
allele frequency 0.00004325). The potential clinical phenotype related to
c.196G>A p.G66S would be important to investigate.
Mutations in CHCHD10 seem to have relatively strict genotype-phenotype
correlations. However, most studies have concentrated on patients with ALS
and/or FTD, and only one non-Finnish CHCHD10 study has been performed
on  SMA  patients  (Morel  et  al.,  2015).  To  confirm  the  phenotype-genotype
correlation, more studies in patients in different cohorts of undetermined
motor neuron disorders, especially CMT2, are needed.
The  basic  function  of  CHCHD10  and  the  mechanism  of  pathogenesis  in
CHCHD10-related diseases remain unclear. There are also a number of
reported mutations with uncertain pathogenicity. Further familial segregation
and functional  studies  are  necessary  to  elucidate  which  mutations  are  truly
pathogenic and how different mutations result in particular phenotypes. It is
also interesting that  even though CHCHD10 is  a  mitochondrial  protein and
other mutations in CHCHD10 cause mitochondrial myopathy, no
mitochondrial  pathology has been observed in SMAJ patients (Jokela et  al.,
2016).  Ongoing studies on muscle biopsy and fibroblasts of c.197G>T p.G66V
homozygote are expected to shed light on the pathomechanism of SMAJ.
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